Live Breaking News & Updates on Recursion pharmaceuticals price performance

Stay informed with the latest breaking news from Recursion pharmaceuticals price performance on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Recursion pharmaceuticals price performance and stay connected to the pulse of your community

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.9% After Insider Selling

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.9% After Insider Selling
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Tina-marriott-larson , Christopher-gibson , Recursion-pharmaceuticals-price-performance , Mubadala-investment-co , Recursion-pharmaceuticals , Blackrock-inc , Recursion-pharmaceuticals-company-profile , Securities-exchange-commission , Hedge-funds-weigh-in-on-recursion-pharmaceuticals , News-ratings-for-recursion-pharmaceuticals-daily , Vanguard-group-inc , Needham-company

Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Increased to $17.00 by Analysts at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […]

Christopher-gibson , Tina-marriott , Investment-management , Needham-company , Recursion-pharmaceuticals-inc , Vanguard-group-inc , Insider-transactions-at-recursion-pharmaceuticals , News-ratings-for-recursion-pharmaceuticals-daily , Recursion-pharmaceuticals-company-profile , Sumitomo-mitsui-trust-holdings-inc , Jpmorgan-chase-co , Blackrock-inc

Baillie Gifford & Co. Trims Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. lowered its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,551,409 shares of the company’s stock after selling 546,221 shares during the quarter. Baillie Gifford & […]

Blake-borgeson , Christopher-gibson , Securities-exchange-commission , Recursion-pharmaceuticals-price-performance , Needham-company , Recursion-pharmaceuticals-inc , Recursion-pharmaceuticals , Quarter-for-recursion-pharmaceuticals , Nasdaq , Norges-bank , Blackrock-inc , Jpmorgan-chase-co

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 9.3%

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 9.3%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

China , Canada , Christopher-gibson , Tina-marriott-larson , News-ratings-for-recursion-pharmaceuticals-daily , First-horizon-advisors-inc , Nasdaq , Baldwin-brothers , Recursion-pharmaceuticals , Jpmorgan-chase-co , Securities-exchange-commission , Needham-company

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $82,800.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $10.35, for a total transaction of $82,800.00. Following the sale, the chief operating officer now owns 414,548 shares […]

Tina-marriott-larson , Vanguard-group-inc , Quarter-for-recursion-pharmaceuticals , Recursion-pharmaceuticals-inc , Norges-bank , Nasdaq , Recursion-pharmaceuticals , News-ratings-for-recursion-pharmaceuticals-daily , Jpmorgan-chase-co , Institutional-trading-of-recursion-pharmaceuticals , Recursion-pharmaceuticals-price-performance , Needham-company

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 25,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CFO Michael Secora sold 25,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $10.45, for a total transaction of $261,250.00. Following the sale, the chief financial officer now directly owns 968,514 shares of the […]

Michael-secora , Recursion-pharmaceuticals-inc , Recursion-pharmaceuticals-price-performance , Nasdaq , Recursion-pharmaceuticals , Blackrock-inc , Jpmorgan-chase-co , Needham-company , Investment-management , News-ratings-for-recursion-pharmaceuticals-daily , Quarter-for-recursion-pharmaceuticals , Vanguard-group-inc

Recursion Pharmaceuticals (NASDAQ:RXRX) PT Lowered to $15.00 at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its price target cut by Needham & Company LLC from $17.00 to $15.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $12.00 to […]

Switzerland , Swiss , Christopher-gibson , Shafique-virani , News-ratings-for-recursion-pharmaceuticals-daily , Needham-company , Vanguard-group-inc , Recursion-pharmaceuticals-price-performance , York-mellon-corp , Securities-exchange-commission , Metlife-investment-management , Recursion-pharmaceuticals-inc

Yong Rong HK Asset Management Ltd Invests $8.77 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Yong Rong HK Asset Management Ltd acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,174,200 shares of the company’s stock, valued at approximately $8,772,000. Recursion Pharmaceuticals accounts for 3.8% of Yong Rong HK Asset […]

Texas , United-states , Blake-borgeson , Christopher-gibson , Needham-company , Keycorp , Allspring-global-investments-holdings , News-ratings-for-recursion-pharmaceuticals-daily , Exchange-traded-concepts , Recursion-pharmaceuticals-price-performance , Nasdaq , Recursion-pharmaceuticals

Shafique Virani Sells 18,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) insider Shafique Virani sold 18,000 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $8.66, for a total value of $155,880.00. Following the transaction, the insider now directly owns 140,351 shares in the company, valued […]

Shafique-virani , Recursion-pharmaceuticals-company-profile , News-ratings-for-recursion-pharmaceuticals-daily , Allspring-global-investments-holdings , Recursion-pharmaceuticals-inc , Needham-company , Keycorp , Securities-exchange-commission , Nasdaq , Institutional-investors-weigh-in-on-recursion-pharmaceuticals , Recursion-pharmaceuticals , Morgan-stanley

Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells 3,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $8.66, for a total value of $25,980.00. Following the sale, the chief operating officer now directly owns 418,782 […]

Tina-marriott-larson , News-ratings-for-recursion-pharmaceuticals-daily , Recursion-pharmaceuticals-inc , Quarter-for-recursion-pharmaceuticals , Recursion-pharmaceuticals , Blackrock-inc , Recursion-pharmaceuticals-price-performance , Norges-bank , Needham-company , Nasdaq , Vanguard-group-inc , Institutional-investors-weigh-in-on-recursion-pharmaceuticals